IMMUNOLOGY2026™ Conference Recordings For Attendees-Targeting Pros1 to improve chemotherapy efficacy and immune anti-tumor response

Targeting Pros1 to improve chemotherapy efficacy and immune anti-tumor response

Video Transcription

Video Summary

The presentation focused on PROS-1, an immune-regulatory protein that helps dying cells be cleared and may also suppress anti-tumor immunity. In melanoma models, cancer cells were found to secrete PROS-1, reducing macrophage function and limiting chemotherapy response. Using PROS-1 knockout B16F10 tumors in mice, the speaker showed that deleting PROS-1 greatly reduced tumor growth after cisplatin treatment and increased immune infiltration, especially B cells and their communication with T cells. Sublethal cisplatin and interferon-gamma both induced PROS-1 expression, while high cisplatin doses did not. This induction appeared to require the interferon-gamma receptor and STAT1 signaling. The speaker also noted that radiation can induce PROS-1 and that PROS-1 inhibition improves response to radiotherapy. Overall, PROS-1 seems to be a tumor-driven mechanism that dampens immune activation and therapy efficacy, with ongoing work to define its broader relevance and therapeutic potential.

Meta Tag

Date April 18, 2026 10:15 AM - 10:30 AM

Room 156

Session Immune Cells in the Tumor Microenvironment I

Speaker Nestor Prieto-Dominguez

Track Tumor Immunology: Cellular Responses and Tumor Microenvironment (TIME)

Year 2026

Keywords

PROS-1

melanoma

cisplatin

immune suppression

radiotherapy

April 18, 2026 10:15 AM - 10:30 AM

156

Immune Cells in the Tumor Microenvironment I

Nestor Prieto-Dominguez

Tumor Immunology: Cellular Responses and Tumor Microenvironment (TIME)

2026